Zymeworks Announces Presentations Highlighting Breadth of Oncology Portfolio at Upcoming Medical Conferences

Zymeworks Announces Presentations Highlighting Breadth of Oncology Portfolio at Upcoming Medical Conferences

Partner presentations reinforce ability of proprietary Azymetric™ platform to develop clinically validated therapeutic antibodiesLong-term outcomes and survival data for Ziihera® (zanidatamab-hrii), which was developed using Azymetric™, to be presented at ASCO and highlight its potential to transform the treatment landscape…

#Zymeworks Forging New Horizons in Cancer Treatment at Global Medical Forums,

'Paving the Path in Oncology: Zymeworks Sets the Stage for Medical Breakthroughs at Premier Global Conferences' In an inspiring move set to influence the oncology landscape significantly, Zymeworks Inc. (Nasdaq: ZYME) is gearing up to highlight its innovative strides in cancer treatment at the most anticipated global medical conferences of the year. Headquartered in Vancouver, British Columbia, this clinical-stage biotechnology company is poised…